These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 33341883

  • 1. Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa.
    Stranix-Chibanda L, Anderson PL, Kacanek D, Hosek S, Huang S, Nematadzira TG, Taulo F, Korutaro V, Nakabiito C, Masenya M, Lypen K, Brown E, Ibrahim ME, Yager J, Wiesner L, Johnston B, Amico KR, Rooney JF, Chakhtoura N, Spiegel HML, Chi BH, IMPAACT 2009 Team.
    Clin Infect Dis; 2021 Oct 05; 73(7):e1893-e1900. PubMed ID: 33341883
    [Abstract] [Full Text] [Related]

  • 2. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review.
    Wu L, Niu X, Brunelli MK, Mugwanya KK.
    Curr HIV/AIDS Rep; 2024 Oct 05; 21(5):264-281. PubMed ID: 39120667
    [Abstract] [Full Text] [Related]

  • 3. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
    Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, Wagner T, Campbell K, Morrow M, Ibrahim M, Buchbinder S, Bushman LR, Kiser JJ, MaWhinney S.
    Antimicrob Agents Chemother; 2018 Jan 05; 62(1):. PubMed ID: 29038282
    [Abstract] [Full Text] [Related]

  • 4. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial.
    Celum CL, Gill K, Morton JF, Stein G, Myers L, Thomas KK, McConnell M, van der Straten A, Baeten JM, Duyver M, Mendel E, Naidoo K, Dallimore J, Wiesner L, Bekker LG.
    J Int AIDS Soc; 2020 Nov 05; 23(11):e25636. PubMed ID: 33247553
    [Abstract] [Full Text] [Related]

  • 5. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
    Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, Pathak S, Mgodi N, Bekker LG, Donnell DJ, Wilson E, Yuha K, Anderson PL, Agyei Y, Noble H, Rose SM, Baeten JM, Fogel JM, Adeyeye A, Wiesner L, Rooney J, Delany-Moretlwe S.
    PLoS Med; 2021 Jun 05; 18(6):e1003670. PubMed ID: 34143779
    [Abstract] [Full Text] [Related]

  • 6. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
    Yager J, Castillo-Mancilla J, Ibrahim ME, Brooks KM, McHugh C, Morrow M, McCallister S, Bushman LR, MaWhinney S, Kiser JJ, Anderson PL.
    J Acquir Immune Defic Syndr; 2020 Jul 01; 84(3):323-330. PubMed ID: 32539288
    [Abstract] [Full Text] [Related]

  • 7. Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial.
    Goldwirt L, Bauer R, Liegeon G, Charreau I, Delaugerre C, Cotte L, Pialou G, Cua E, Laghzal A, Buschman L, Anderson PL, Mourah S, Meyer L, Molina JM, ANRS IPERGAY Study Group.
    J Antimicrob Chemother; 2021 Sep 15; 76(10):2675-2680. PubMed ID: 34278433
    [Abstract] [Full Text] [Related]

  • 8. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
    Pyra M, Anderson PL, Hendrix CW, Heffron R, Mugwanya K, Haberer JE, Thomas KK, Celum C, Donnell D, Marzinke MA, Bukusi EA, Mugo NR, Asiimwe S, Katabira E, Baeten JM, Partners Demonstration Study Team.
    AIDS; 2018 Aug 24; 32(13):1891-1898. PubMed ID: 29894385
    [Abstract] [Full Text] [Related]

  • 9. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
    Castillo-Mancilla JR, Zheng JH, Rower JE, Meditz A, Gardner EM, Predhomme J, Fernandez C, Langness J, Kiser JJ, Bushman LR, Anderson PL.
    AIDS Res Hum Retroviruses; 2013 Feb 24; 29(2):384-90. PubMed ID: 22935078
    [Abstract] [Full Text] [Related]

  • 10. Adherence challenges with daily oral pre-exposure prophylaxis during pregnancy and the postpartum period in South African women: a cohort study.
    Joseph Davey D, Nyemba DC, Castillo-Mancilla J, Wiesner L, Norman J, Mvududu R, Mashele N, Johnson LF, Bekker LG, Gorbach P, Coates TJ, Myer L.
    J Int AIDS Soc; 2022 Dec 24; 25(12):e26044. PubMed ID: 36480171
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study.
    Odayar J, Orrell C, Phillips TK, Hu NC, Kabanda S, Malaba TR, Allerton J, Wiesner L, Hsiao NY, Castillo-Mancilla J, Lesosky M, Myer L.
    Clin Infect Dis; 2022 Sep 14; 75(5):761-767. PubMed ID: 34979553
    [Abstract] [Full Text] [Related]

  • 15. Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women.
    Castillo-Mancilla JR, Searls K, Caraway P, Zheng JH, Gardner EM, Predhomme J, Bushman LR, Anderson PL, Meditz AL.
    AIDS Res Hum Retroviruses; 2015 Apr 14; 31(4):428-32. PubMed ID: 25328112
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.
    Velloza J, Donnell D, Hosek S, Anderson PL, Chirenje ZM, Mgodi N, Bekker LG, Marzinke MA, Delany-Moretlwe S, Celum C.
    Lancet HIV; 2022 Oct 14; 9(10):e680-e689. PubMed ID: 36087612
    [Abstract] [Full Text] [Related]

  • 20. Development of a tool to assess HIV prevention readiness of adolescent girls and young women in HPTN 082 study.
    Beauchamp G, Hosek S, Donnell DJ, Chan KCG, Flaherty BP, Anderson PL, Dye BJ, Mgodi N, Bekker LG, Delany-Moretlwe S, Celum C, HPTN 082 study team.
    PLoS One; 2023 Oct 14; 18(2):e0281728. PubMed ID: 36827440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.